Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis
about
Effect of High N-Acetylcysteine Concentrations on Antibiotic Activity against a Large Collection of Respiratory PathogensOxidative Stress in COPD: Sources, Markers, and Potential MechanismsDrug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.Can Big Data Analyses Help Speed Up the Clinical Development of Mucoactive Drugs for Symptomatic RTIs?Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.Amorphous silica nanoparticles trigger vascular endothelial cell injury through apoptosis and autophagy via reactive oxygen species-mediated MAPK/Bcl-2 and PI3K/Akt/mTOR signaling.Bmi1 plays an important role in dentin and mandible homeostasis by maintaining redox balance.Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation.Oxidation pathway and exacerbations in COPD: the role of NAC.Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis.Treatment options for moderate-to-very severe chronic obstructive pulmonary disease.Bringing Stability to the Chronic Obstructive Pulmonary Disease Patient: Clinical and Pharmacological Considerations for Frequent Exacerbators.Transcription Factor NF-κB: An Update on Intervention Strategies.Pharmacological treatments in asthma-affected horses: A pair-wise and network meta-analysis.Optimizing bronchodilation in the prevention of COPD exacerbationsEpidemiology and impact of chronic bronchitis in chronic obstructive pulmonary disease.Effects of N-acetyl-L-cysteine on the membrane vesicle release and growth of respiratory pathogens.Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.Antibiotics for treatment of acute exacerbation of chronic obstructive pulmonary disease: a network meta-analysis.The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis.Recommendations for the pharmacological treatment of COPD: questions and answers.Integrative Medicine for Respiratory Conditions: Asthma and Chronic Obstructive Pulmonary Disease.Multidimensional approach for the proper management of a complex chronic patient with chronic obstructive pulmonary disease.An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?The Challenges of Precision Medicine in COPD.Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.Diaphragm Muscle Weakness Following Acute Sustained Hypoxic Stress in the Mouse Is Prevented by Pretreatment with N-Acetyl Cysteine.Redox-dependent thiol modifications: implications for the release of extracellular vesicles.H-NMR-based metabolic profiling of healthy individuals and high-resolution CT-classified phenotypes of COPD with treatment of tiotropium bromide
P2860
Q28820811-53E12D73-9FCD-410E-9F58-42A6925FEAE2Q29247910-CA3B01FF-7460-4F40-B630-E7876B1BEDE7Q30249747-B0ED104D-A235-4F5C-9F88-DF921BACD488Q31038964-FB6C94E5-9A32-4A70-AB99-77DD18CC3840Q34550471-E9CBE1A1-1A89-42A7-A6C5-D8BF89DBED9AQ37344272-83EB7DAF-0BC0-4C39-A624-3D942A74545BQ37448119-4A5E4598-4151-4182-81F6-BA74389D57D6Q37602620-2063A896-87F0-4E03-BA81-35BE583AA412Q38633304-2B77BDE0-5069-44DE-8CA6-6C935026FD15Q38655574-52EF10BF-844E-412D-BA54-14F5760833DCQ38740756-62A7415B-A600-441A-B54D-1E951AC782E1Q38751226-B6500A47-4872-4200-B989-4A90D8DFCBB8Q38802627-37D5332E-BA82-4E5E-BFF9-06DF3681CE6AQ38906820-0AD9816B-691E-41FE-BEAD-C4EB708F33B8Q39386571-DD458266-8565-457B-9DD1-DCFA48A6FEA0Q40086644-024D1290-2FC7-420D-B168-1317A10BDCC3Q40237147-20E85CC3-AC35-4909-B915-050A9B14B9F9Q40598255-958D86E8-276A-425C-B4E3-A04804CB641EQ47127548-C9278732-8426-4BE5-B025-8EC5A574C3F3Q47177016-F211FCF3-8809-4E7F-8D59-F8504612660FQ47272746-721B0464-49E1-433B-835A-05DA6F7BEE2EQ47648795-CA02C80B-D14A-4688-ACE7-D6FACF15F24CQ47680491-395C1470-B9CA-4E2F-836B-86AE7AF1E228Q47728819-1525EEB4-F0AE-4A44-83F8-716535107B5DQ47962475-C7CF7D2E-8FB0-4ADB-BB72-F3469B3CCD7AQ47984024-5C0DE183-C8B7-4C10-BB1C-B136B425C561Q55019335-D83B53FC-7D6F-4C33-AE85-FE4E0ED63EFAQ55237882-C5AAA13F-9815-4E80-BF39-E08AF4DD9C77Q57491079-953F94F6-82E1-4E4C-916E-DCA9A6385924
P2860
Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Influence of N-acetylcysteine ...... exacerbations: a meta-analysis
@ast
Influence of N-acetylcysteine ...... exacerbations: a meta-analysis
@en
Influence of N-acetylcysteine ...... exacerbations: a meta-analysis
@nl
type
label
Influence of N-acetylcysteine ...... exacerbations: a meta-analysis
@ast
Influence of N-acetylcysteine ...... exacerbations: a meta-analysis
@en
Influence of N-acetylcysteine ...... exacerbations: a meta-analysis
@nl
prefLabel
Influence of N-acetylcysteine ...... exacerbations: a meta-analysis
@ast
Influence of N-acetylcysteine ...... exacerbations: a meta-analysis
@en
Influence of N-acetylcysteine ...... exacerbations: a meta-analysis
@nl
P2093
P3181
P1476
Influence of N-acetylcysteine ...... exacerbations: a meta-analysis
@en
P2093
Alexander G Chuchalin
Clive Page
Josè Jardim
Maria Gabriella Matera
Mario Cazzola
P304
P3181
P356
10.1183/16000617.00002215
P407
P577
2015-09-01T00:00:00Z